Novel insights into mechanisms of inhibition of colonic motility by loperamide.
constipation
enteric nervous system
loperamide
opiate
peristalsis
Journal
Frontiers in neuroscience
ISSN: 1662-4548
Titre abrégé: Front Neurosci
Pays: Switzerland
ID NLM: 101478481
Informations de publication
Date de publication:
2024
2024
Historique:
received:
29
04
2024
accepted:
05
08
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
13
9
2024
Statut:
epublish
Résumé
It is well known that opiates slow gastrointestinal (GI) transit, via suppression of enteric cholinergic neurotransmission throughout the GI tract, particularly the large intestine where constipation is commonly induced. It is not clear whether there is uniform suppression of enteric neurotransmission and colonic motility across the full length of the colon. Here, we investigated whether regional changes in colonic motility occur using the peripherally-restricted mu opioid agonist, loperamide to inhibit colonic motor complexes (CMCs) in isolated mouse colon. High-resolution video imaging was performed to monitor colonic wall diameter on isolated whole mouse colon. Regional changes in the effects of loperamide on the pattern generator underlying cyclical CMCs and their propagation across the full length of large intestine were determined. The sensitivity of CMCs to loperamide across the length of colon varied significantly. Although there was a dose-dependent inhibition of CMCs with increasing concentrations of loperamide (10 nM - 1 μM), a major observation was that in the mid and distal colon, CMCs were abolished at low doses of loperamide (100 nM), while in the proximal colon, CMCs persisted at the same low concentration, albeit at a significantly slower frequency. Propagation velocity of CMCs was significantly reduced by 46%. The inhibitory effects of loperamide on CMCs were reversed by naloxone (1 μM). Naloxone alone did not change ongoing CMC characteristics. The results show pronounced differences in the inhibitory action of loperamide across the length of large intestine. The most potent effect of loperamide to retard colonic transit occurred between the proximal colon and mid/distal regions of colon. One of the possibilities as to why this occurs is because the greatest density of mu opioid receptors are located on interneurons responsible for neuro-neuronal transmission underlying CMCs propagation between the proximal and mid/distal colon. The absence of effect of naloxone alone on CMC characteristics suggest that the mu opioid receptor has little ongoing constitutive activity under our recording conditions.
Sections du résumé
Background
UNASSIGNED
It is well known that opiates slow gastrointestinal (GI) transit, via suppression of enteric cholinergic neurotransmission throughout the GI tract, particularly the large intestine where constipation is commonly induced. It is not clear whether there is uniform suppression of enteric neurotransmission and colonic motility across the full length of the colon. Here, we investigated whether regional changes in colonic motility occur using the peripherally-restricted mu opioid agonist, loperamide to inhibit colonic motor complexes (CMCs) in isolated mouse colon.
Methods
UNASSIGNED
High-resolution video imaging was performed to monitor colonic wall diameter on isolated whole mouse colon. Regional changes in the effects of loperamide on the pattern generator underlying cyclical CMCs and their propagation across the full length of large intestine were determined.
Results
UNASSIGNED
The sensitivity of CMCs to loperamide across the length of colon varied significantly. Although there was a dose-dependent inhibition of CMCs with increasing concentrations of loperamide (10 nM - 1 μM), a major observation was that in the mid and distal colon, CMCs were abolished at low doses of loperamide (100 nM), while in the proximal colon, CMCs persisted at the same low concentration, albeit at a significantly slower frequency. Propagation velocity of CMCs was significantly reduced by 46%. The inhibitory effects of loperamide on CMCs were reversed by naloxone (1 μM). Naloxone alone did not change ongoing CMC characteristics.
Discussion
UNASSIGNED
The results show pronounced differences in the inhibitory action of loperamide across the length of large intestine. The most potent effect of loperamide to retard colonic transit occurred between the proximal colon and mid/distal regions of colon. One of the possibilities as to why this occurs is because the greatest density of mu opioid receptors are located on interneurons responsible for neuro-neuronal transmission underlying CMCs propagation between the proximal and mid/distal colon. The absence of effect of naloxone alone on CMC characteristics suggest that the mu opioid receptor has little ongoing constitutive activity under our recording conditions.
Identifiants
pubmed: 39268036
doi: 10.3389/fnins.2024.1424936
pmc: PMC11390470
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1424936Informations de copyright
Copyright © 2024 Parkar, Spencer, Wiklendt, Olson, Young, Janssen, McNabb and Dalziel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Commun Biol. 2021 Aug 10;4(1):955
pubmed: 34376798
J Physiol. 1998 Feb 1;506 ( Pt 3):843-56
pubmed: 9503342
Nat Commun. 2014;5:3326
pubmed: 24561718
Anat Rec. 2001 Jan 1;262(1):58-70
pubmed: 11146429
Handb Exp Pharmacol. 2017;239:363-378
pubmed: 28204957
Adv Exp Med Biol. 2014;817:39-71
pubmed: 24997029
Neuroscience. 1997 Nov;81(2):579-91
pubmed: 9300443
Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:3-16
pubmed: 15357847
Scand J Gastroenterol Suppl. 1987;130:65-6
pubmed: 2820051
Neurogastroenterol Motil. 2002 Dec;14(6):657-65
pubmed: 12464088
Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G930-8
pubmed: 17158255
Eur J Pharmacol. 2007 Nov 21;574(1):66-70
pubmed: 17632101
Gastroenterology. 2010 Feb;138(2):659-70 670.e1-2
pubmed: 19782081
Neurogastroenterol Motil. 1995 Jun;7(2):89-96
pubmed: 7621324
Br J Pharmacol. 1992 Aug;106(4):1004-10
pubmed: 1356564
J Pharmacol Exp Ther. 2016 Jun;357(3):520-8
pubmed: 27068812
Auton Neurosci. 2000 Nov 1;84(3):162-8
pubmed: 11111848
Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):338-351
pubmed: 32152479
J Gastroenterol. 2014 Jan;49(1):24-45
pubmed: 23397116
Br J Pharmacol. 2001 Jan;132(2):507-17
pubmed: 11159701
Front Neurosci. 2014 May 08;8:96
pubmed: 24847200
Life Sci. 2006 Feb 28;78(14):1610-6
pubmed: 16289621
Jpn J Pharmacol. 1978 Dec;28(6):873-82
pubmed: 745310
Front Physiol. 2011 Dec 21;2:98
pubmed: 22203805
PLoS One. 2012;7(9):e45251
pubmed: 23028881
Gastroenterology. 2011 Sep;141(3):982-991.e18
pubmed: 21699782
Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G996-G1008
pubmed: 18276829
Jpn J Pharmacol. 2000 Apr;82(4):343-9
pubmed: 10875755
Nat Rev Gastroenterol Hepatol. 2012 Mar 06;9(5):286-94
pubmed: 22392290
Regul Pept. 2009 Jun 5;155(1-3):11-7
pubmed: 19345246
Neurogastroenterol Motil. 2022 Nov;34(11):e14442
pubmed: 36054796
J Physiol. 2016 Aug 1;594(15):4325-38
pubmed: 26990461
J Gen Physiol. 2021 Sep 6;153(9):
pubmed: 34357374
BMC Gastroenterol. 2010 Aug 19;10:95
pubmed: 20723249
Life Sci. 1980 Dec 8;27(23):2211-7
pubmed: 7207014
Nat Rev Gastroenterol Hepatol. 2019 Sep;16(9):559-579
pubmed: 31296967
Neurogastroenterol Motil. 2013 Aug;25(8):677-85
pubmed: 23593931
Sci Rep. 2018 Apr 12;8(1):5923
pubmed: 29651005
J Comp Neurol. 2003 Apr 14;458(4):404-11
pubmed: 12619074
Neurogastroenterol Motil. 2016 Aug;28(8):1241-51
pubmed: 27028044
Biochem Pharmacol. 1979 Apr 15;28(8):1433-4
pubmed: 444310
Neurogastroenterol Motil. 1997 Jun;9(2):99-107
pubmed: 9198085
J Physiol. 2003 Dec 15;553(Pt 3):881-93
pubmed: 14514874